Additional file 3 of Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results

Osuga, Yutaka, Seki, Yoshifumi, Tanimoto, Masataka, Kusumoto, Takeru, Kudou, Kentarou, Terakawa, Naoki
2021 · doi:10.6084/m9.figshare.14821132 · W6901828003
OA: green CC0
🔓 Open OA copy View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-10 ⓘ

This study presents the change from baseline in the mean of the B&B score for pelvic pain, dysmenorrhea, and dyspareunia by visit for relugolix in women with endometriosis-associated pain.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Additional file 3. Change from baseline in mean of B&B score for pelvic pain, dysmenorrhea, and dyspareunia by visit.

My notes (saved in your browser only)

Condition tags

endometriosisdysmenorrheadyspareunia

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (11)

Source provenance

openalex
last seen: 2026-05-13T18:34:15.591076+00:00
License: CC0 · commercial use OK